Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2018756#aggregation> ?p ?o. }
Showing items 1 to 50 of
50
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B338063.
- aggregation creator B338064.
- aggregation creator B338065.
- aggregation creator B338066.
- aggregation creator B338067.
- aggregation creator B338068.
- aggregation creator B338069.
- aggregation creator B338070.
- aggregation creator B338071.
- aggregation creator B338072.
- aggregation creator B338073.
- aggregation creator B338074.
- aggregation creator B338075.
- aggregation creator B338076.
- aggregation creator B338077.
- aggregation creator B338078.
- aggregation creator B338079.
- aggregation creator B338080.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 2018756.bibtex.
- aggregation hasFormat 2018756.csv.
- aggregation hasFormat 2018756.dc.
- aggregation hasFormat 2018756.didl.
- aggregation hasFormat 2018756.doc.
- aggregation hasFormat 2018756.json.
- aggregation hasFormat 2018756.mets.
- aggregation hasFormat 2018756.mods.
- aggregation hasFormat 2018756.rdf.
- aggregation hasFormat 2018756.ris.
- aggregation hasFormat 2018756.txt.
- aggregation hasFormat 2018756.xls.
- aggregation hasFormat 2018756.yaml.
- aggregation isPartOf urn:issn:0016-5085.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped".
- aggregation abstract "BACKGROUND & AIMS: It is important to determine whether infliximab therapy can be safely interrupted in patients with Crohn's disease who have undergone a period of prolonged remission. We assessed the risk of relapse after infliximab therapy was discontinued in patients on combined maintenance therapy with antimetabolites and identified factors associated with relapse. METHODS: We performed a prospective study of 115 patients with Crohn's disease who were treated for at least 1 year with scheduled infliximab and an antimetabolite and had been in corticosteroid-free remission for at least 6 months. Infliximab was stopped, and patients were followed up for at least 1 year. We associated demographic, clinical, and biologic factors with time to relapse using a Cox model. RESULTS: After a median follow-up period of 28 months, 52 of the 115 patients experienced a relapse; the 1-year relapse rate was 43.9% +/- 5.0%. Based on multivariable analysis, risk factors for relapse included male sex, the absence of surgical resection, leukocyte counts >6.0 x 10(9)/L, and levels of hemoglobin <= 145 g/L, C-reactive protein >= 5.0 mg/L, and fecal calprotectin >= 300 mu g/g. Patients with no more than 2 of these risk factors (approximately 29% of the study population) had a 15% risk of relapse within 1 year. Re-treatment with infliximab was effective and well tolerated in 88% of patients who experienced a relapse. CONCLUSIONS: Approximately 50% of patients with Crohn's disease who were treated for at least 1 year with infliximab and an antimetabolite agent experienced a relapse within 1 year after discontinuation of infliximab. However, patients with a low risk of relapse can be identified using a combination of clinical and biologic markers.".
- aggregation authorList BK635084.
- aggregation endPage "70".
- aggregation issue "1".
- aggregation startPage "63".
- aggregation volume "142".
- aggregation aggregates 2023143.
- aggregation isDescribedBy 2018756.
- aggregation similarTo j.gastro.2011.09.034.
- aggregation similarTo LU-2018756.